Abstract:What's new? The combination of immunotherapy and antiangiogenic agents for the treatment of refractory solid tumors remains to be further investigated. Here, the authors conducted the prospective, single‐arm, nonrandomized, phase II APICAL‐RST trial to investigate the efficacy and safety of the oral multikinase inhibitor anlotinib plus PD‐1 inhibitor in refractory solid tumors. The regimen demonstrated substantial clinical activity and manageable toxicity among heavily pretreated, pan‐cancer patients. The clinical benefits were consistent across different histological or molecular subgroups. The results from the APICAL‐RST trial support anlotinib plus PD‐1 inhibitor as an effective regimen in heavily‐treated, refractory, metastatic solid tumors. The combination of immunotherapy and antiangiogenic agents for the treatment of refractory solid tumor has not been well investigated. Thus, our study aimed to evaluate the efficacy and safety of a new regimen of anlotinib plus PD‐1 inhibitor to treat refractory solid tumor. APICAL‐RST is an investigator‐initiated, open‐label, single‐arm, phase II trial in patients with heavily treated, refractory, metastatic solid tumor. Eligible patients experienced disease progression during prior therapy without further effective regimen. All patients received anlotinib and PD‐1 inhibitor. The primary endpoints were objective response and disease control rates. The secondary endpoints included the ratio of progression‐free survival 2 (PFS2)/PFS1, overall survival (OS) and safety. Forty‐one patients were recruited in our study; 9 patients achieved a confirmed partial response and 21 patients had stable disease. Objective response rate and disease control rate were 22.0% and 73.2% in the intention‐to‐treat cohort, and 24.3% and 81.1% in the efficacy‐evaluable cohort, respectively. A total of 63.4% (95% confidence interval [CI]: 46.9%‐77.4%) of the patients (26/41) presented PFS2/PFS1 >1.3. The median OS was 16.8 months (range: 8.23‐24.4), and the 12‐ and 36‐month OS rates were 62.8% and 28.9%, respectively. No significant association was observed between concomitant mutation and efficacy. Thirty‐one (75.6%) patients experienced at least one treatment‐related adverse event. The most common adverse events were hypothyroidism, hand‐foot syndrome and malaise. This phase II trial showed that anlotinib plus PD‐1 inhibitor exhibits favorable efficacy and tolerability in patients with refractory solid tumor.

Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity Via Immunogenic Cell Death and Macrophage Reprogramming

Anlotinib enhanced CD8 + T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer

Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer

Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer

Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy

Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials

Anlotinib combined with the PD-L1 blockade exerts the potent anti-tumor immunity in renal cancer treatment

Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study

Anlotinib potentiates anti‐PD1 immunotherapy via transferrin receptor‐dependent CD8+ T‐cell infiltration in hepatocellular carcinoma

Penpulimab combined with anlotinib therapy in patients with advanced refractory solid tumors: A single-center, observational, prospective study.

Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma

Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non–small-cell lung cancer

The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‐1 antibody suppresses the progression of non‐small cell lung cancer tumors by enhancing immunocompetence

Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer

[Combination therapy based on PD-1/PD-L1 blocking in the treatment of non-small cell lung cancer]

Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy

Pan‐cancer efficacy and safety of anlotinib plus PD‐1 inhibitor in refractory solid tumor: A single‐arm, open‐label, phase II trial

Combined Inhibition Of Tgf- Signaling And The Pd-L1 Immune Checkpoint Is Differentially Effective In Tumor Models

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer

Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer.

Amplifying T cell‐mediated antitumor immune responses in nonsmall cell lung cancer through photodynamic therapy and anti‐PD1